Compare FBIZ & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBIZ | SPRY |
|---|---|---|
| Founded | 1909 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.7M | 558.9M |
| IPO Year | 2012 | 2020 |
| Metric | FBIZ | SPRY |
|---|---|---|
| Price | $72.76 | $4.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $66.00 | $40.00 |
| AVG Volume (30 Days) | 40.2K | ★ 1.4M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.41% | N/A |
| EPS Growth | ★ 14.23 | N/A |
| EPS | ★ 3.28 | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $15.69 | $87.40 |
| Revenue Next Year | $8.47 | $81.64 |
| P/E Ratio | $21.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $46.07 | $4.91 |
| 52 Week High | $73.48 | $13.15 |
| Indicator | FBIZ | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 58.87 | 34.83 |
| Support Level | $69.91 | $5.04 |
| Resistance Level | $73.48 | $8.61 |
| Average True Range (ATR) | 1.43 | 0.26 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 75.63 | 3.64 |
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, delivering a full line of commercial banking products, including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically, all the business activity functioned through the region of the United States.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.